Business Wire

Pfizer’s ELREXFIO™ Receives U.S. FDA Accelerated Approval for Relapsed or Refractory Multiple Myeloma

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval to ELREXFIO™ (elranatamab-bcmm) for the treatment of ...
Monthly Prescribing Reference

FDA Grants Accelerated Approval to Elrexfio for Relapsed/Refractory Multiple Myeloma

Credit: Pfizer. Elrexfio is supplied as a ready-to-use solution in 76mg/1.9 mL (40mg/mL) and 44mg/1.1 mL (40mg/mL) single-dose vials. The Food and Drug Administration (FDA) has granted accelerated ...
Business Wire

ELREXFIO™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory Multiple Myeloma

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced detailed overall survival (OS) results from the Phase 2 MagnetisMM-3 study of ELREXFIO™ (elranatamab-bcmm) in patients with heavily ...
FiercePharma

With FDA approval for Elrexfio, Pfizer brings multiple myeloma battle to Johnson & Johnson

Another off-the-shelf, BCMA-directed drug has arrived for the treatment of multiple myeloma. Monday, the FDA approved Pfizer’s Elrexfio, or elranatamab, for patients with multiple myeloma who've tried ...
Nasdaq

Pfizer's ELREXFIO Receives Conditional Marketing Authorization From European Commission

(RTTNews) - Pfizer Inc. (PFE) on Friday announced that its prescription medication, ELREXFIO (elranatamab) has received conditional marketing authorization from the European Commission (EC) to treat ...